In fact, in the ARIEL2 trial of the PARP inhibitor rucaparib in ovarian cancer, tumor biopsies revealed positive associations between alterations in BRCA1 or RAD51C, high genomic loss of heterozygosity (gLOH), and increased response to rucaparib [102]. Here, PARP1 is linked to neoplasm.